new glp 1 agonist novo nordisk said on Tuesday its triple UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to Novo Nordisk expands oral GLP-1
Description
The mechanism of action of semaglutide involves binding to GLP-1 receptors in multiple tissues throughout the body
( Source ) The continued growth in uptake of GLP-1 agonists is uncertain
Appetite suppressants are restricted due to the adverse neurological effects they can cause
doi: 10.3748/wjg.v23.i17.3150
received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, GSK, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Takeda and Vianex
